Neuropace Inc (NPCE) FinancialsNPCEFinancialNeuropace Inc

Evaluating the bottom line, NeuroPace, Inc. maintains a gross margin of 82.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -22.53%, while the net margin is -27.16%. These profitability ratios, combined with a Return on Equity (ROE) of -103.27%, provide a clear picture of how effectively NPCE converts its operational activities into shareholder value.

In the context of the broader market, NPCE competes directly with industry leaders such as CLPT and SGHT. With a market capitalization of $506.97M, it holds a leading position in the sector. When comparing efficiency, NPCE's gross margin of 82.83% stands against CLPT's 61.67% and SGHT's 90.96%. Such benchmarking helps identify whether NeuroPace, Inc. is trading at a premium or discount relative to its financial performance.

Neuropace has demonstrated a strong revenue growth trajectory with Q1 2026 revenue of $22.1 million, exceeding expectations, and a projected revenue growth of 21%-23% for the RNS system sales. Despite recent losses, the gross margin has improved significantly, reaching 82.83% in Q2 2026, indicating effective cost management and profitability potential.